Provided by Tiger Trade Technology Pte. Ltd.

Tharimmune Inc.

4.74
0.0000
Volume:- -
Turnover:- -
Market Cap:187.37M
PE:-1.21
High:4.74
Open:4.74
Low:4.74
Close:4.74
52wk High:9.08
52wk Low:0.9520
Shares:39.53M
Float Shares:35.11M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9051
EPS(LYR):-9.4096
ROE:-225.01%
ROA:-99.79%
PB:30.44
PE(LYR):-0.50

Loading ...

Company Profile

Company Name:
Tharimmune Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
3
Office Location:
34 Shrewsbury Avenue,Suite 1C,Red Bank,New Jersey,United States
Zip Code:
07701
Fax:
- -
Introduction:
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.